Rhumbline Advisers Fulcrum Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 87,208 shares of FULC stock, worth $396,796. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,208
Previous 91,432
4.62%
Holding current value
$396,796
Previous $566,000
45.05%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding FULC
# of Institutions
150Shares Held
52.2MCall Options Held
6.91MPut Options Held
1.9M-
Ra Capital Management, L.P. Boston, MA10.2MShares$46.5 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$23.9 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$21.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$21.7 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$14.9 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $237M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...